法尼醇X受体激动剂奥贝胆酸

发布时间：2018-06-27 12:58

本文选题：奥贝胆酸 + 熊去氧胆酸　；参考：《现代药物与临床》2016年03期

【摘要】：奥贝胆酸是一种治疗原发性胆汁性肝硬化和非酒精性脂肪肝的新型候选药物,由美国Intercept制药公司研发,其机制主要是通过激动法尼醇X受体,调节相关基因,影响胆汁酸的合成、分泌、转运和吸收。临床研究表明,对熊去氧胆酸不能完全耐受的患者,通过服用奥贝胆酸能够明显改善碱性磷酸酶和血清胆红素的水平,提示奥贝胆酸的临床效果可能优于现有药物熊去氧胆酸。将从奥贝胆酸的药物概况、相关背景、合成路线、药理作用、临床前及临床试验研究以及安全性评价方面进行简述。
[Abstract]:Obercholic acid is a novel candidate drug for the treatment of primary biliary cirrhosis and non-alcoholic fatty liver. Affects the synthesis, secretion, transport and absorption of bile acids. Clinical studies have shown that patients who are intolerant of ursodeoxycholic acid can obviously improve the level of alkaline phosphatase and serum bilirubin by taking Obercholic acid, which suggests that the clinical effect of aubercholic acid may be better than that of the existing drug ursodeoxycholic acid. In this paper, the general situation, related background, synthetic route, pharmacological action, preclinical and clinical trial studies and safety evaluation of Obercholic acid are reviewed.
【作者单位】：天津药物研究院天津市新药设计与发现重点实验室;天津医科大学;天津中医药大学;
【基金】：国家自然科学基金资助项目(81503130) 天津市应用基础与前沿技术研究计划(14JCQNJC13000)
【分类号】：R975

【相似文献】